NEWARK,
Calif., Nov. 3, 2022 /PRNewswire/ --
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the
Company") announced today that three abstracts related to the
Company's rusfertide program have been accepted as poster
presentations at the 64th Annual Meeting and Exposition
of the American Society of Hematology (ASH), taking place
December 10-13, 2022 at the Ernest N.
Morial Convention Center in New Orleans,
Louisiana.
- Poster Presentation 1:
Title: VERIFY: A Phase 3 Study
of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with
Polycythemia Vera
Session Name: 634. Myeloproliferative Syndromes: Clinical and
Epidemiological: Poster I
Session Date: Saturday, December 10,
2022
Presentation Time: 5:30 PM - 7:30 PM
CT.
- Poster Presentation 2:
Title: Subgroup Analysis of
Adverse Events Following Rusfertide Dosing in REVIVE: A Phase 2
Study of Patients with Polycythemia Vera
Session Name: 634. Myeloproliferative Syndromes: Clinical and
Epidemiological: Poster II
Session Date: Sunday, December 11,
2022
Presentation Time: 6:00 PM - 8:00 PM
CT.
- Poster Presentation 3:
Title: Rusfertide
Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in
Conjunction with Phlebotomy in Mouse Model for Hereditary
Hemochromatosis
Session Name: 102. Iron Homeostasis and Biology: Poster II
Session Date: Sunday, December 11,
2022
Presentation Time: 6:00 PM - 8:00 PM
CT.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
peptide-based new chemical entities rusfertide and PN-235 in
advanced stages of clinical development, both derived from the
Company's proprietary technology platform. Rusfertide, a mimetic of
the natural hormone hepcidin, is the Company's lead drug candidate
currently in a global Phase 3 stage of development. The VERIFY
(Phase 3) and REVIVE (Phase 2) studies of rusfertide in
polycythemia vera are ongoing. Protagonist owns all marketing
rights to rusfertide.
Protagonist has partnered with Janssen Biotech, Inc. on the
development of PN-235 (JNJ-77242113) in moderate-to-severe
psoriasis and inflammatory bowel disease. PN-235 is currently in
multiple studies in psoriasis, led by Janssen.
Protagonist is headquartered in Newark, California. For more information on
Protagonist, please visit the Company's website at
www.protagonist-inc.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential benefits of
rusfertide to patients. In some cases, you can identify these
statements by forward-looking words such as "anticipate,"
"believe," "may," "will," "expect," or the negative or plural of
these words or similar expressions. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our ability to develop and commercialize our product candidates,
our ability to earn milestone payments under our collaboration
agreement with Janssen Biotech, the impact of the current COVID-19
pandemic on our discovery and development efforts, the impact of
the ongoing military conflict in Ukraine and Russia on any future studies, our ability to
use and expand our programs to build a pipeline of product
candidates, our ability to obtain and maintain regulatory approval
of our product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. Additional information concerning these and other
risk factors affecting our business can be found in our periodic
filings with the Securities and Exchange Commission, including
under the heading "Risk Factors" contained in our most recently
filed periodic reports on Form 10-K and Form 10-Q filed with the
Securities and Exchange Commission. Forward-looking statements are
not guarantees of future performance, and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press
release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-poster-presentations-at-the-american-society-of-hematology-2022-annual-meeting-301667179.html
SOURCE Protagonist Therapeutics, Inc.